Clinical landscape in cancer research. Volume 5 /
Cancer, a multifaceted disease, remains the leading cause of death worldwide. Ongoing research and technological advancements are continually improving the human understanding of newer treatment options. This book series aims to provide wide-ranging insights into the current landscape of cancer rese...
| Corporate Author: | |
|---|---|
| Other Authors: | , |
| Format: | eBook |
| Language: | English |
| Published: |
London, United Kingdom :
Academic Press,
2025.
|
| Subjects: | |
| Online Access: | Connect to the full text of this electronic book |
Table of Contents:
- Front Cover
- Clinical Landscape in Cancer Research
- Clinical Landscape in Cancer Research
- Copyright
- Contents
- Contributors
- About the editors
- Preface
- Drug Delivery Systems Landscape in Cancer Research (Vol. 1)
- Biomarker Landscape in Cancer Research (Vol. 2)
- Diagnostics Landscape in Cancer Research (Vol. 3)
- Preclinical Landscape in Cancer Research (Vol. 4)
- Clinical Landscape in Cancer Research (Vol. 5)
- 1
- Pancreatic cancer: Advances in clinical research
- Introduction
- Pathophysiology of pancreatic carcinoma
- Indications and manifestations
- Type
- Epidemiology of pancreatic carcinoma
- Genetic processes pancreatic carcinoma
- Pain mechanisms of pancreatic carcinoma
- Worlds statistics
- Genetic mutations
- KRAS mutation
- Tumor suppressor genes
- Dysregulated signaling pathways
- PI3K/AKT/mTOR pathway
- MAPK pathway
- Tumor microenvironment
- Desmoplasia
- Immune cell infiltration
- Metabolic reprogramming
- Warburg effect
- Glutamine dependence
- Epigenetic alterations
- DNA methylation
- Histone modifications
- Tumor heterogeneity
- Intratumoral heterogeneity
- Immune evasion mechanisms
- Challenges and considerations
- Types of biopharmaceuticals
- Clinical trial phases
- Targeted mechanisms and approaches
- Clinical trial design and considerations
- Challenges and envisage
- Types of regenerative therapies
- Cellular therapies
- Stem cell therapy
- Tissue engineering
- Bioengineered pancreas tissues
- Immunotherapy-based regenerative approaches
- Dendritic cell vaccines
- Clinical trial phases and design
- Challenges and considerations
- Future directions
- Conclusion
- References
- 2
- Spleen cancer: Advances in clinical research
- Introduction
- Factors involved in spleen cancer
- Cellular mechanism
- Clinical trial landscape.
- Generic drugs-clinical trials ()
- Zanubrutinib in Japanese participants with B-cell malignancies (NCT04172246)
- A study to investigate the efficacy and safety of bendamustine compared with bendamustine+obinutuzumab (GA101) in participa ...
- Obinutuzumab and ibrutinib as front-line therapy in treating patients with indolent nonHodgkin's lymphomas- NCT03198026
- Study of acalabrutinib and tafasitamab in MZL patients- NCT04646395
- Efficacy and safety study of idelalisib in participants with indolent B-cell nonHodgkin's lymphomas (DELTA)- NCT01282424
- Carfilzomib with or without rituximab in the treatment of Waldenstrom macroglobulinemia or marginal zone lymphoma-NCT03269552
- UCN-01 and fludarabine in treating patients with recurrent or refractory lymphoma or leukemia-NCT00019838
- Phase II trial of LMB-2, fludarabine and cyclophosphamide for adult T-cell leukemia-NCT00924170
- Doxorubicin hydrochloride, cyclophosphamide, and paclitaxel with or without bevacizumab in treating patients with lymph nod ...
- Comparison between rituximab plus Zanubrutinib versus rituximab monotherapy in untreated SMZL patients (RITZ)- NCT05735834
- Phase II study of SAR302503 in patients with myelofibrosis- NCT01420770
- An efficacy and safety study of fedratinib compared to best available therapy in subjects with DIPSS-intermediate or high-r ...
- Study with SAR302503 in patients with polycythemia vera or essential thrombocythemia-NCT01420783
- Study to evaluate the activity of two dose levels of Imetelstat in participants with intermediate-2 or high-risk myelofibro ...
- A study to evaluate the efficacy of venetoclax monotherapy in relapsed/refractory participants with chronic lymphocytic leu ...
- A study of ibrutinib in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphoc.
- Comparison of the treatments of obinutuzumab+venetoclax versus obinutuzumab+chlorambucil in patients with chronic lymphocyt ...
- Study of effectiveness of Axicabtagene Ciloleucel compared to standard of care therapy in patients with relapsed/refractory ...
- Efficacy and safety study of lenalidomide plus R-CHOP chemotherapy versus placebo plus R-CHOP chemotherapy in untreated ABC ...
- Biopharmaceutical clinical trials ()
- A study of selinexor monotherapy in subjects with Janus Kinase inhibitor naïve myelofibrosis and moderate thrombocytopenia ...
- Vaccine therapy for treating patients with previously untreated chronic lymphocytic leukemia- NCT01976520
- A study of VAC85135, a Neoantigen Vaccine Regimen, concurrently administered with Ipilimumab for the treatment of myeloprol ...
- Vaccine response with NT-I7- NCT04054752
- Vaccine therapy with or without cryosurgery in treating patients with residual, relapsed, or refractory B-cell nonHodgkin l ...
- Feasibility of autologous tumor cell-TLR9 agonist vaccination for metastatic colorectal cancer- NCT00780988
- Monoclonal antibody therapy in treating patients with lymphoma or colon cancer that has not responded to vaccine therapy- N ...
- Vaccine therapy in treating patients who have undergone a donor stem cell transplant and have cytomegalovirus infection tha ...
- Busulfan, melphalan, and thiotepa in treating patients who are undergoing an autologous stem cell transplant for Hodgkin's ...
- Assessment of Galectin-9 in rheumatoid arthritis and Its correlation with disease activity- NCT05422313
- System biology of spleen deficiency syndrome
- NCT02915393
- Safety, tolerability and preliminary efficacy of engineered red blood cell in patients with advanced malignancies (Reboot-1.
- Study of traditional Chinese medicine syndrome of hepatocellular carcinoma and colorectal cancer based on system science- N ...
- A clinical study using MEDI-551 in adult participants with relapsed or refractory advanced B-cell malignancies- NCT00983619
- Considerate study
- splenic stimulation for RA- NCT05003310
- Regenerative therapies ()
- Lithium carbonate in treating patients with acute intestinal graft-versus-host-disease after donor stem cell transplant
- N ...
- Pentostatin, cyclophosphamide, and rituximab with or without bevacizumab in treating patients with B-cell chronic lymphocyt ...
- A trial of Lenvatinib plus pembrolizumab in participants with hepatocellular carcinoma- NCT03006926
- Solar: Efficacy and safety of cobomarsen (MRG-106) versus active comparator in subjects with mycosis fungoides (SOLAR)- NCT ...
- Historical trials
- Clinical trials on vaccine therapy
- Vaccine therapy in treating patients with previously treated stage II-III HER2-positive breast cancer- NCT01632332
- Autologous vaccine for follicular lymphoma- NCT01022255
- Conclusion
- References
- 3
- CNS cancer: Advances in clinical research
- Introduction
- CNS cancer clinical landscape
- Highlights of CNS cancer clinicals
- Drugs
- Procedures and radiation
- Devices
- Biologics
- Molecular
- Conclusion
- References
- 4
- Skin cancer: Advances in clinical research
- Introduction
- Types of skin cancer
- Factors affecting skin cancer progression
- UV rays
- Skin color
- Immunogenic morbidity
- Indoor tanning
- Age
- Viral agent
- World statistics for skin cancer
- Oncogenic pathways
- WNT signaling pathway
- G-protein-coupled receptor-responsive skin cancer progression
- MAPK pathway
- Phosphatidylinositol-3-kinase pathway
- Clinical trials
- Generic drugs
- Imatinib mesylate
- Intralesional versus systemic methotrexate.
- Vorinostat
- Nintedanib combined with paclitaxel
- Carboplatin and temozolomide
- Pembrolizumab with imatinib mesylate
- Tazarotene
- Diclofenac and difluoromethylornithine
- Sirolimus
- Cemiplimab with SAR444245
- Nivolumaband/orrelatlimab
- Camrelizumab
- Talimogene Laherparepvec
- Taxoprexin (DHA-paclitaxel)
- Azacitidine combined with pembrolizumab
- Vatalanib
- Carboplatin, paclitaxel, bevacizumab, ± everolimus
- Encorafenib, binimetinib, and nivolumab
- Vaccines and biopharmaceutical clinical trials
- Regenerative therapies
- mRNA trials
- Current challenges for skin cancer clinical trials
- Financial problems
- Clinical trial accrual and completion
- Conclusion
- References
- 5
- Lung cancer: Advances in clinical research
- Introduction
- Introduction to lung cancer
- Types of lung cancer
- Histological classification of lung cancer
- Factors affecting lung cancer
- Genetic risk factors
- Family history and high-penetrance genes
- Genetic polymorphisms
- Tobacco consumption and smoking
- Chronic inflammation from infections and other medical conditions
- Pollution
- World statistics
- Molecular biology
- Clinical trial landscape
- Generic drugs-clinical trials
- Docetaxel alone versus cisplatin (CDDP)+docetaxel
- Sintilimab±bevacizumab biosimilar IBI305 combined with pemetrexed and cisplatin
- Metronomic oral vinorelbine and triweekly cisplatin
- Anlotinib
- Irinotecan plus cisplatin with or without simvastatin
- Serplulimab
- Camrelizumab plus apatinib
- Ramucirumab plus atezolizumab
- Nivolumab plus ipilimumab
- Tiragolumab plus atezolizumab
- Eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab
- Osimertinib
- Crizotinib
- Lorlatinib versus crizotinib
- Tepotinib
- Vaccines and immunotherapy
- mRNA trials
- Inhalation and systemic chemotherapy.